RESET® is a removable endoscopic intestinal liner described for use alongside lifestyle and medical care. This guide explains how the device works, who may need assessment, what the evidence reports, what risks require attention and why planned removal and follow-up matter.
Updated 15 October 2026. This is educational content, not a diagnosis, prescription or guarantee of treatment availability.
At a glance
This is not gastric bypass surgery and it is not a permanent implant. It does not remove part of the stomach, and it should not be described as a cure for obesity or type 2 diabetes. The benefit-risk decision depends on current device instructions, the person’s medical history, local regulatory status and reliable follow-up.
How food passes through a duodenal-jejunal bypass liner is a simplified educational explanation. The treating team should explain the device supplied for your care and its current instructions for use.
| Question | Key information |
|---|---|
| What is it? | A thin, flexible intestinal liner approximately 60 cm long. |
| Where does it work? | In the upper small intestine, rather than inside the stomach. |
| How is it placed? | Endoscopically through the mouth, usually under general anaesthesia. |
| Does it require incisions? | No abdominal incisions are needed for routine placement. |
| How long does treatment last? | No longer than 9 months under the supplied manufacturer guidance. |
| Is removal necessary? | Yes. Planned removal is an essential part of treatment. |
Clinical assessment
The list is not a substitute for a clinician’s assessment. Never stop or change a medicine without the prescriber’s direction.
How it works
Medical, dietary, anaesthetic and practical checks are completed before a decision is made.
The liner is introduced through the mouth and secured near the start of the small intestine under the agreed anaesthesia plan.
Follow-up supports diet, hydration, symptoms and metabolic monitoring; planned removal is essential and must not be missed.
This video is supplied for general education. External video content is not a personal medical recommendation and does not confirm local availability.
Patient journey
Step 1 · Before placement
The assessment reviews your history, examination, blood tests, medicines, anatomy, metabolic goals and ability to complete the programme. The clinical team confirms whether the current instructions for use permit treatment.
Step 2 · Placement
The liner is introduced through the mouth with an endoscope and positioned in the upper small intestine. The supplied materials describe routine placement without abdominal incisions, usually under general anaesthesia.
Step 3 · After placement
The early diet progresses from liquids to pureed or soft foods and then to regular textures only when the treating team permits. Follow-up checks symptoms, hydration, nutrition, medicines, metabolic markers and the plan for removal.
Recovery and follow-up
Days 1–7
The supplied booklet describes a liquid diet with nutritional support. Nausea, cramping, discomfort and vomiting can occur; the actual plan must be individualised.
Days 8–14
Move to pureed or soft foods only as directed, chew carefully and monitor hydration and symptoms.
Day 14 onward
A return to regular textures is gradual and clinician-led. Avoid foods that conflict with the device guidance, including coarse, stringy or hard-to-chew foods.
Up to 9 months
The supplied manufacturer guidance sets a maximum implant duration of 9 months. A removal appointment should be planned; the device must not be left in place indefinitely.
Before travelling, ask for a written follow-up and emergency plan, carry the device identification information and confirm where removal or urgent endoscopy would be available. The booklet warns against NSAIDs unless the treating clinician specifically advises otherwise. Follow the prescribing team’s instructions for acid-reducing medicines, diabetes medicines and every other medication.
Published evidence
| Outcome | Reported average change | Patients with paired measurements |
|---|---|---|
| Body weight | Reduction of 13.3 kg | 811 |
| HbA1c | Reduction of 1.3 percentage points | 646 |
1,022
patients in the worldwide registry
4.2%
serious adverse-event rate reported in that registry
9 months
maximum implant duration in the supplied guidance
Published data can have selection, follow-up and reporting limitations. Ask which device, protocol, population, follow-up duration and outcome definition apply to any number quoted during a consultation.
A September 2025 Morphic Medical announcement described a larger real-world registry than the 1,022-patient dataset above. These figures are reported by the device manufacturer and should be checked against the underlying presentation or publication before being used to make an individual decision.
1,298 patients
A 2025 manufacturer announcement described a real-world registry across 37 centres in 12 countries.
18.9% average total body-weight reduction
The same announcement reported this group-level average; it is not a personal forecast.
1.3 percentage-point HbA1c reduction
The reported average change was greater in people who started with higher HbA1c.
77% maintained improvement at 3 years
The announcement described maintenance after removal, but follow-up populations and definitions still need review.
Nine-month protocol
The manufacturer described a nine-month approach as delivering the reported benefits with fewer complications than a 12-month approach.
Regulatory and regional context
Morphic's regional information presents RESET® as a device intended as an adjunct to lifestyle and/or medicines for obesity with at least one cardiometabolic risk factor, such as type 2 diabetes or dyslipidaemia. Turkish legal status and centre-specific supply still require separate confirmation.
The manufacturer's US information describes RESET® as investigational and links it to the STEP-1 clinical study. US study criteria, regulatory language and trial participation requirements must not be applied as an Istanbul eligibility rule.
Morphic's device-literature portal says product information varies by geography and should match the country where the procedure occurs. Ask for the current Türkiye-specific instructions for use, patient information and emergency guidance before proceeding.
Safety first
Worsening or severe abdominal pain, fever, right-upper-quadrant pain or chills, persistent or severe nausea and vomiting, severe diarrhoea, bloody vomit, black stools, dizziness, confusion or fainting.
Do not wait for a routine clinic reply. Contact local emergency services or the nearest emergency department and tell them that you have an intestinal liner.
Compare options
| Question | RESET® | Gastric bypass | ESG / sleeve |
|---|---|---|---|
| Anatomy | Removable liner in upper small intestine | Permanent stomach and intestinal reconstruction | ESG reshapes stomach; sleeve removes stomach tissue |
| Access | Endoscopic placement and removal | Laparoscopic surgery | ESG endoscopic; sleeve laparoscopic |
| Main commitment | Diet, monitoring and planned removal | Lifelong nutritional monitoring and supplements | Long-term dietary and metabolic follow-up |
| Evidence question | Device-specific data and local status require checking | Established procedure with a different risk and benefit profile | Different evidence, indications and risks |
International patient planning
Answers for patients
RESET® is a removable, approximately 60 cm fluoropolymer liner placed endoscopically in the upper small intestine. It is intended to be used with lifestyle and medical care, not as a stand-alone cure for obesity or diabetes.
They are related concepts: each uses a liner in the upper intestine to alter nutrient contact. The exact device, anchoring system, evidence, instructions for use and regulatory status must be checked for the product being considered. Do not assume data from one device automatically apply to another.
Routine placement and removal are endoscopic procedures through the mouth and do not require abdominal incisions. They still require anaesthesia, trained clinicians, medical assessment and a plan for managing complications or early removal.
A person with obesity or cardiometabolic risk may request an assessment, but eligibility is individual. The clinician must confirm anatomy, comorbidities, medicines, current instructions for use, local availability and the ability to complete diet and follow-up before treatment can be discussed as an option.
The programme may include medical history, examination, blood tests, metabolic assessment, medication review, anaesthetic review, diet and lifestyle planning, and endoscopic or other investigations when clinically indicated.
Some people return to routine activity in two or three days, while others need a week or longer. Early nausea, discomfort, cramping and vomiting are possible. The staged liquid, soft-food and texture-progression plan is clinician-led.
In a worldwide registry of 1,022 patients, paired measurements reported an average body-weight reduction of 13.3 kg among 811 patients and an HbA1c reduction of 1.3 percentage points among 646 patients. These are reported group averages, not a prediction for an individual.
Risks include pain, nausea, vomiting, bleeding, migration, obstruction, pancreatitis, infection, liver abscess, cholecystitis and early removal. The registry reported 43 serious adverse events among 1,022 patients (4.2%). Severe injury or death is possible with serious complications, so urgent symptoms need immediate medical attention.
Yes. Planned removal is essential and the supplied manufacturer guidance limits implantation to no longer than 9 months. Removal is performed endoscopically unless a complication requires a different approach.
Availability, Turkish registration, centre-specific supply, team competence and clinician approval must be confirmed before any treatment is presented as bookable. This page is an assessment-led educational preview, not a promise that Istanbul Bariatric Center currently offers the device.
Publication status
Istanbul Bariatric Center can collect your questions and medical background for an assessment-led discussion. Local registration, supply, centre-specific availability, treating-team competence and genuine clinician approval must be confirmed before RESET® can be described as a bookable service.
Request a clinical assessment